Predictive and prognostic biomarkers in colorectal cancer

Abstract

Colorectal cancer is the third most common cancer and the second leading cause of cancer-related death in the United States. Three quarters of patients diagnosed with colorectal cancer will have early stage disease and despite surgical resection for curative intent, approximately 20%–25% of patients will recur with their disease within five years. The other 25% will present with advanced or metastatic disease and clinicians are faced with the challenge of choosing the most appropriate therapy for individual patients. Despite multiple treatment options which are now available and concomitant improvements in survival, advanced colorectal cancer remains universally fatal. The challenge for clinicians is to identify prognostic and predictive biomarkers that can assist in tailoring available treatments for an individual patient to improve clinical outcomes. This review will summarize current and future biomarkers in colorectal cancer and discuss their utility in managing patient care.

References

[1] Aaltonen L A, Peltomäki P, Leach F S, Sistonen P, Pylkkänen L, Mecklin J P, Järvinen H, Powell S M, Jen J, Hamilton S R, . (1993). Clues to the pathogenesis of familial colorectal cancer. Science, 260(5109): 812–816

[2] Amado R G, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman D J, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson S D, Chang D D (2008). Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol, 26(10): 1626–1634

[3] André T, Bensmaine M A, Louvet C, François E, Lucas V, Desseigne F, Beerblock K, Bouché O, Carola E, Merrouche Y, Morvan F, Dupont-André G, de Gramont A (1999). Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J Clin Oncol, 17(11): 3560–3568

[4] Andreyev H J, Norman A R, Cunningham D, Oates J, Dix B R, Iacopetta B J, Young J, Walsh T, Ward R, Hawkins N, Beranek M, Jandik P, Benamouzig R, Jullian E, Laurent-Puig P, Olschwang S, Muller O, Hoffmann I, Rabes H M, Zietz C, Troungos C, Valavanis C, Yuen S T, Ho J W, Croke C T, O’Donoghue D P, Giaretti W, Rapallo A, Russo A, Bazan V, Tanaka M, Omura K, Azuma T, Ohkusa T, Fujimori T, Ono Y, Pauly M, Faber C, Glaesener R, de Goeij A F, Arends J W, Andersen S N, Lövig T, Breivik J, Gaudernack G, Clausen O P, De Angelis P D, Meling G I, Rognum T O, Smith R, Goh H S, Font A, Rosell R, Sun X F, Zhang H, Benhattar J, Losi L, Lee J Q, Wang S T, Clarke P A, Bell S, Quirke P, Bubb V J, Piris J, Cruickshank N R, Morton D, Fox J C, Al-Mulla F, Lees N, Hall C N, Snary D, Wilkinson K, Dillon D, Costa J, Pricolo V E, Finkelstein S D, Thebo J S, Senagore A J, Halter S A, Wadler S, Malik S, Krtolica K, Urosevic N (2001). Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study. Br J Cancer, 85(5): 692–696

[5] Andreyev H J, Norman A R, Cunningham D, Oates J R, Clarke P A (1998). Kirsten ras mutations in patients with colorectal cancer: the multicenter “RASCAL” study. J Natl Cancer Inst, 90(9): 675–684

[6] Arnaud J P, Koehl C, Adloff M (1980). Carcinoembryonic antigen (CEA) in diagnosis and prognosis of colorectal carcinoma. Dis Colon Rectum, 23(3): 141–144

[7] Atkinson A J, Colburn W A, Degruttola V G,βDe Mets D L,βDowning DO G J,βHoth D F, Oates J A, Peck C C,βSchooley R T, Spilker B A,βWoodcock J,βZeger S L (2001). Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther, 69(3): 89–95

[8] Augenlicht L H, Wahrman M Z, Halsey H, Anderson L, Taylor J, Lipkin M (1987). Expression of cloned sequences in biopsies of human colonic tissue and in colonic carcinoma cells induced to differentiate in vitro. Cancer Res, 47(22): 6017–6021

[9] August D A, Sugarbaker P H, Ottow R T, Gianola F J, Schneider P D (1985). Hepatic resection of colorectal metastases. Influence of clinical factors and adjuvant intraperitoneal 5-fluorouracil via Tenckhoff catheter on survival. Ann Surg, 201(2): 210–218

[10] Barrier A, Roser F, Boëlle P Y, Franc B, Tse C, Brault D, Lacaine F, Houry S, Callard P, Penna C, Debuire B, Flahault A, Dudoit S, Lemoine A (2007). Prognosis of stage II colon cancer by non-neoplastic mucosa gene expression profiling. Oncogene, 26(18): 2642–2648

[11] Begent R H (1984). The value of carcinoembryonic antigen measurement in clinical practice. Ann Clin Biochem, 21(Pt 4): 231–238

[12] Bertagnolli M M, Niedzwiecki D, Compton C C, Hahn H P, Hall M, Damas B, Jewell S D, Mayer R J, Goldberg R M, Saltz L B, Warren R S, Redston M (2009). Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J Clin Oncol, 27(11): 1814–1821

[13] Bertucci F, Salas S, Eysteries S, Nasser V, Finetti P, Ginestier C, Charafe-Jauffret E, Loriod B, Bachelart L, Montfort J, Victorero G, Viret F, Ollendorff V, Fert V, Giovaninni M, Delpero J R, Nguyen C, Viens P, Monges G, Birnbaum D, Houlgatte R (2004). Gene expression profiling of colon cancer by DNA microarrays and correlation with histoclinical parameters. Oncogene, 23(7): 1377–1391

[14] Bokemeyer C, Bondarenko I, Hartmann J T, De Braud F G, Celik I, Koralewski P(2010). Biomarkers predictive for outcome on patients with metastatic colorectal cancer (mCRC) treated with first-line FOLFOX4 plus or minus cetuximab: Updated data from the OPUS study. Gastrointestinal Cancer Symposium, Abstract No. 428

[15] Boland C R, Sato J, Appelman H D, Bresalier R S, Feinberg A P (1995). Microallelotyping defines the sequence and tempo of allelic losses at tumour suppressor gene loci during colorectal cancer progression. Nat Med, 1(9): 902–909

[16] Buc E, Vartanian M D, Darcha C, Déchelotte P, Pezet D (2005). Guanylyl cyclase C as a reliable immunohistochemical marker and its ligand Escherichia coli heat-stable enterotoxin as a potential protein-delivering vehicle for colorectal cancer cells. Eur J Cancer, 41(11): 1618–1627

[17] Carlson M R (2009). Previstage GCC colorectal cancer staging test: a new molecular test to identify lymph node metastases and provide more accurate information about the stage of patients with colorectal cancer. Mol Diagn Ther, 13(1): 11–14

[18] Chapman M A, Buckley D, Henson D B, Armitage N C (1998). Preoperative carcinoembryonic antigen is related to tumour stage and long-term survival in colorectal cancer. Br J Cancer, 78(10): 1346–1349

[19] Panel T M E (1996). Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. J Clin Oncol, 14(10): 2843–2877

[20] De Roock W, Jonker D J, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S, Lamba S, Arena S, Frattini M, Piessevaux H, Van Cutsem E, O’Callaghan C J, Khambata-Ford S, Zalcberg J R, Simes J, Karapetis C S, Bardelli A, Tejpar S (2010). Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA, 304: 1812–1820

[21] Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A (2008). Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol, 26(35): 5705–5712

[22] Douillard J Y, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocákova I, Ruff P, Błasińska-Morawiec M, Šmakal M, Canon J L, Rother M, Oliner K S, Wolf M, Gansert J (2010). Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol, 28(31): 4697–4705

[23] Fearon E R, Cho K R, Nigro J M, Kern S E, Simons J W, Ruppert J M, Hamilton S R, Preisinger A C, Thomas G, Kinzler K W, et (1990). Identification of a chromosome 18q gene that is altered in colorectal cancers. Science, 247(4938): 49–56

[24] Fearon E R, Vogelstein B (1990). A genetic model for colorectal tumorigenesis. Cell, 61(5): 759–767

[25] Fine B M, Amler L (2009). Predictive biomarkers in the development of oncology drugs: a therapeutic industry perspective. Clin Pharmacol Ther, 85(5): 535–538

[26] Fletcher R H (1986). Carcinoembryonic antigen. Ann Intern Med, 104(1): 66–73

[27] Frederiksen C M, Knudsen S, Laurberg S, Ørntoft T F (2003). Classification of Dukes’ B and C colorectal cancers using expression arrays. J Cancer Res Clin Oncol, 129(5): 263–271

[28] Frick G S, Pitari G M, Weinberg D S, Hyslop T, Schulz S, Waldman S A (2005). Guanylyl cyclase C: a molecular marker for staging and postoperative surveillance of patients with colorectal cancer. Expert Rev Mol Diagn, 5(5): 701–713

[30] Gold P, Freedman S O (1965). Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J Exp Med, 121(3): 439–462

[31] Golub T R (2001). Genome-wide views of cancer. N Engl J Med, 344(8): 601–602

[32] Golub T R, Slonim D K, Tamayo P, Huard C, Gaasenbeek M, Mesirov J P, Coller H, Loh M L, Downing J R, Caligiuri M A, Bloomfield C D, Lander E S (1999). Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science, 286(5439): 531–537

[33] Grady W M (2004). Genomic instability and colon cancer. Cancer Metastasis Rev, 23(1-2): 11–27

[34] Gray R, Barnwell J, McConkey C, Hills R K, Williams N S, Kerr D J, Quasar Collaborative Group (2007). Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet, 370(9604): 2020–2029

[35] Greene F L P D, Balch C M, Page D L, Haller D G, Fleming I D, Morrow M, Fritz A G (2002). AJCC Cancer Staging Manual, 6th Edition. New York: Springer

[36] Gryfe R, Kim H, Hsieh E T, Aronson M D, Holowaty E J, Bull S B, Redston M, Gallinger S (2000). Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med, 342(2): 69–77

[37] Halling K C, French A J, McDonnell S K, Burgart L J, Schaid D J, Peterson B J, Moon-Tasson L, Mahoney M R, Sargent D J, O’Connell M J, Witzig T E, Farr G H Jr, Goldberg R M, Thibodeau S N (1999). Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers. J Natl Cancer Inst, 91(15): 1295–1303

[38] Harrison L E, Guillem J G, Paty P, Cohen A M (1997). Preoperative carcinoembryonic antigen predicts outcomes in node-negative colon cancer patients: a multivariate analysis of 572 patients. J Am Coll Surg, 185(1): 55–59

[39] Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004). Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med, 350(23): 2335–2342

[40] Ionov Y, Peinado M A, Malkhosyan S, Shibata D, Perucho M (1993). Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature, 363(6429): 558–561

[41] Ishizuka D, Shirai Y, Sakai Y, Hatakeyama K (2001). Colorectal carcinoma liver metastases: clinical significance of preoperative measurement of serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels. Int J Colorectal Dis, 16(1): 32–37

[42] Jemal A, Siegel R, Xu J, Ward E (2010). Cancer statistics, 2010. CA Cancer J Clin, 60(5): 277–300

[43] Jover R, Zapater P, Castells A, Llor X, Andreu M, Cubiella J, Balaguer F, Sempere L, Xicola R M, Bujanda L, Reñé J M, Clofent J, Bessa X, Morillas J D, Nicolás-Pérez D, Pons E, Payá A, Alenda C, the Gastrointestinal Oncology Group of the Spanish Gastroenterological Association (2009). The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status. Eur J Cancer, 45(3): 365–373

[44] Kallioniemi O P, Wagner U, Kononen J, Sauter G (2001). Tissue microarray technology for high-throughput molecular profiling of cancer. Hum Mol Genet, 10(7): 657–662

[45] Karapetis C S, Khambata-Ford S, Jonker D J, O’Callaghan C J, Tu D, Tebbutt N C, Simes R J, Chalchal H, Shapiro J D, Robitaille S, Price T J, Shepherd L, Au H J, Langer C, Moore M J, Zalcberg J R (2008). K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med, 359(17): 1757–1765

[46] Khine K, Smith D R, Goh H S (1994). High frequency of allelic deletion on chromosome 17p in advanced colorectal cancer. Cancer, 73(1): 28–35

[47] Koch M, Kienle P, Kastrati D, Antolovic D, Schmidt J, Herfarth C, von Knebel Doeberitz M, Weitz J (2006). Prognostic impact of hematogenous tumor cell dissemination in patients with stage II colorectal cancer. Int J Cancer, 118(12): 3072–3077

[48] Kohne C, Stroiakovski D, Chang-Chien C, Lim R, Pintér T, Bodoky G, Stroh C, Celik I, Rougier P, Van Cutsem E (2009). Predictive biomarkers to improve treatment of metastatic colorectal cancer (mCRC): outcomes with cetuximab plus FOLFIRI in the CRYSTAL trial. J Clin Oncol, 27: 15s (Suppl; abstr 4068)

[49] Kressner U, Bjørheim J, Westring S, Wahlberg S S, Påhlman L, Glimelius B, Lindmark G, Lindblom A, Børresen-Dale A L (1998). Ki-ras mutations and prognosis in colorectal cancer. Eur J Cancer, 34(4): 518–521

[50] Lin Y H, Friederichs J, Black M A, Mages J, Rosenberg R, Guilford P J, Phillips V, Thompson-Fawcett M, Kasabov N, Toro T, Merrie A E, van Rij A, Yoon H S, McCall J L, Siewert J R, Holzmann B, Reeve A E (2007). Multiple gene expression classifiers from different array platforms predict poor prognosis of colorectal cancer. Clin Cancer Res, 13: 498–507

[51] Locker GY, Hamilton S, Harris J, Jessup J M, Kemeny N, Macdonald J S, Somerfield M R, Hayes D F, Bast R C Jr (2006). ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol, 24: 5313–5327

[52] Loupakis F, Ruzzo A, Cremolini C, Vincenzi B, Salvatore L, Santini D, Masi G, Stasi I, Canestrari E, Rulli E, Floriani I, Bencardino K, Galluccio N, Catalano V, Tonini G, Magnani M, Fontanini G, Basolo F, Falcone A, Graziano F (2009). KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer, 101(4): 715–721

[53] McShane L M, Altman D G, Sauerbrei W, Taube S E, Gion M, Clark G M, the Statistics Subcommittee of NCI-EORTC Working Group on Cancer Diagnostics (2006a). REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat, 100(2): 229–235

[54] McShane L M, Altman D G, Sauerbrei W, Taube S E, Gion M, Clark G M, the Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics (2006b). Reporting recommendations for tumor marker prognostic studies (remark). Exp Oncol, 28(2): 99–105

[55] Mejia A, Waldman S A (2008). Previstage GCC test for staging patients with colorectal cancer. Expert Rev Mol Diagn, 8(5): 571–578

[56] Minoo P, Moyer M P, Jass J R (2007). Role of BRAF-V600E in the serrated pathway of colorectal tumourigenesis. J Pathol, 212(2): 124–133

[57] Nevins J R, Potti A (2007). Mining gene expression profiles: expression signatures as cancer phenotypes. Nat Rev Genet, 8(8): 601–609

[58] Nishioka M, Shimada M, Kurita N, Iwata T, Morimoto S, Yoshikawa K, Higashijima J, Miyatani T (2011). Gene expression profile can predict pathological response to preoperative chemoradio therapy in rectal cancer. Cancer Genomics Proteomics, 8(2): 87–92

[59] O’Connell M J, Lavery I, Yothers G, Paik S, Clark-Langone K M, Lopatin M, Watson D, Baehner F L, Shak S, Baker J, Cowens J W, Wolmark N (2010). Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. J Clin Oncol, 28(25): 3937–3944

[60] Ogino S, Nosho K, Irahara N, Shima K, Baba Y, Kirkner G J, Meyerhardt J A, Fuchs C S (2009). Prognostic significance and molecular associations of 18q loss of heterozygosity: a cohort study of microsatellite stable colorectal cancers. J Clin Oncol, 27(27): 4591–4598

[61] Perou C M, Sørlie T, Eisen M B, van de Rijn M, Jeffrey S S, Rees C A, Pollack J R, Ross D T, Johnsen H, Akslen L A, Fluge O, Pergamenschikov A, Williams C, Zhu S X, Lønning P E, Børresen-Dale A L, Brown P O, Botstein D (2000). Molecular portraits of human breast tumours. Nature, 406(6797): 747–752

[62] Pietra N, Sarli L, Costi R, Ouchemi C, Grattarola M, Peracchia A (1998). Role of follow-up in management of local recurrences of colorectal cancer: a prospective, randomized study. Dis Colon Rectum, 41(9): 1127–1133

[63] Popat S, Houlston R S (2005). A systematic review and meta-analysis of the relationship between chromosome 18q genotype, DCC status and colorectal cancer prognosis. Eur J Cancer, 41(14): 2060–2070

[64] Popat S, Hubner R, Houlston R S (2005). Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol, 23(3): 609–618

[65] Prenen H, De Schutter J, Jacobs B, De Roock W, Biesmans B, Claes B, Lambrechts D, Van Cutsem E, Tejpar S (2009). PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. Clin Cancer Res, 15(9): 3184–3188

[66] Ribic C M, Sargent D J, Moore M J, Thibodeau S N, French A J, Goldberg R M, Hamilton S R, Laurent-Puig P, Gryfe R, Shepherd L E, Tu D, Redston M, Gallinger S (2003). Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med, 349(3): 247–257

[67] Rosenwald A, Wright G, Chan W C, Connors J M, Campo E, Fisher R I, Gascoyne R D, Muller-Hermelink H K, Smeland E B, Giltnane J M, Hurt E M, Zhao H, Averett L, Yang L, Wilson W H, Jaffe E S, Simon R, Klausner R D, Powell J, Duffey P L, Longo D L, Greiner T C, Weisenburger D D, Sanger W G, Dave B J, Lynch J C, Vose J, Armitage J O, Montserrat E, López-Guillermo A, Grogan T M, Miller T P, LeBlanc M, Ott G, Kvaloy S, Delabie J, Holte H, Krajci P, Stokke T, Staudt L M, the Lymphoma/Leukemia Molecular Profiling Project (2002). The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med, 346(25): 1937–1947

[68] Roth A D, Tejpar S, Yan P, Fiocca R, Dietrich D, Delorenzi M, Labianca R, Cunningham D, Van Cutsem E, Bosman F (2009). Stage-specific prognostic value of molecular markers in colon cancer: Results of the translational study on the PETACC 3-EORTC 40993-SAKK 60–00 trial. J Clin Oncol, 27: 15S (Suppl; abstr 4002)

[69] Salazar R, Roepman P, Capella G, Moreno V, Simon I, Dreezen C, Lopez-Doriga A, Santos C, Marijnen C, Westerga J, Bruin S, Kerr D, Kuppen P, van de Velde C, Morreau H, Van Velthuysen L, Glas A M, Van’t Veer L J, Tollenaar R (2011). Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol, 29(1): 17–24

[70] Saltz L B, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang T S, Rivera F, Couture F, Sirzén F, Cassidy J (2008). Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol, 26(12): 2013–2019

[71] Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J,βSzabo S,βYan H, Gazdar A,β Powell S M, Riggins G J,βWillson J K V, Markowitz S, Kinzler K W, Vogelstein B,βVelculescu V E (2004). High frequency of mutations of the PIK3CA gene in human cancers. Science, 304: 554

[72] Sartore-Bianchi A, Martini M, Molinari F, Veronese S, Nichelatti M, Artale S, Di Nicolantonio F, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A (2009). PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 69:1851–1857

[73] Sargent D J, Marsoni S, Monges G, Thibodeau S N, Labianca R, Hamilton S R, French A J, Kabat B, Foster N R, Torri V, Ribic C, Grothey A, Moore M, Zaniboni A, Seitz J F, Sinicrope F, Gallinger S (2010). Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol, 28(20): 3219–3226

[74] Shibata D, Reale M A, Lavin P, Silverman M, Fearon E R, Steele G Jr, Jessup J M, Loda M, Summerhayes I C (1996). The DCC protein and prognosis in colorectal cancer. N Engl J Med, 335(23): 1727–1732

[75] Shipp M A, Ross K N, Tamayo P, Weng A P, Kutok J L, Aguiar R C, Gaasenbeek M, Angelo M, Reich M, Pinkus G S, Ray T S, Koval M A, Last K W, Norton A, Lister T A, Mesirov J, Neuberg D S, Lander E S, Aster J C, Golub T R (2002). Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med, 8(1): 68–74

[76] Sugarbaker P H (1976). Carcinoembryonic antigen (CEA) assays in obstructive colorectal cancer. Ann Surg, 184(6): 752–757

[77] Sun X F, Rütten S, Zhang H, Nordenskjöld B (1999). Expression of the deleted in colorectal cancer gene is related to prognosis in DNA diploid and low proliferative colorectal adenocarcinoma. J Clin Oncol, 17(6): 1745–1750

[78] Tejpar S, Bosman F,Delorenzi M, Fiocca R, Yan P, Klingbiel D, Dietrich D, Van Cutsem E, Labianca R, Roth A (2009). Microsatellite instability (MSI) in stage II and III colon cancer treated with 5FU-LV or 5FU-LV and irinotecan (PETACC 3-EORTC 40993-SAKK 60/00 trial). J Clin Oncol, 27:15S (Suppl; Abstr 4001)

[79] Thompson J A, Grunert F, Zimmermann W (1991). Carcinoembryonic antigen gene family: molecular biology and clinical perspectives. J Clin Lab Anal, 5(5): 344–366

[80] Tol J, Nagtegaal I D, Punt C J (2009). BRAF mutation in metastatic colorectal cancer. N Engl J Med, 361(1): 98–99

[81] Uen Y H, Lin S R, Wu D C, Su Y C, Wu J Y, Cheng T L, Chi C W, Wang J Y (2007). Prognostic significance of multiple molecular markers for patients with stage II colorectal cancer undergoing curative resection. Ann Surg, 246(6): 1040–1046

[82] Vogelstein B, Fearon E R, Hamilton S R, Kern S E, Preisinger A C, Leppert M, Nakamura Y, White R, Smits A M, Bos J L (1988). Genetic alterations during colorectal-tumor development. N Engl J Med, 319(9): 525–532

[83] Wanebo H J, Rao B, Pinsky C M, Hoffman R G, Stearns M, Schwartz M K, Oettgen H F (1978). Preoperative carcinoembryonic antigen level as a prognostic indicator in colorectal cancer. N Engl J Med, 299(9): 448–451

[84] Wang J Y, Lin S R, Wu D C, Lu C Y, Yu F J, Hsieh J S, Cheng T L, Koay L B, Uen Y H (2007). Multiple molecular markers as predictors of colorectal cancer in patients with normal perioperative serum carcinoembryonic antigen levels. Clin Cancer Res, 13(8): 2406–2413

[85] Wang Y, Jatkoe T, Zhang Y, Mutch M G, Talantov D, Jiang J, McLeod H L, Atkins D (2004). Gene expression profiles and molecular markers to predict recurrence of Dukes’B colon cancer. J Clin Oncol, 22: 1564–1571

[86] Wichmann M W, Lau-Werner U, Müller C, Hornung H M, Stieber P, Schildberg F W, the Colorectal Cancer Study Group (2000). Carcinoembryonic antigen for the detection of recurrent disease following curative resection of colorectal cancer. Anticancer Res, 20(6D): 4953–4955

[87] Wiratkapun S, Kraemer M, Seow-Choen F, Ho Y H, Eu K W (2001). High preoperative serum carcinoembryonic antigen predicts metastatic recurrence in potentially curative colonic cancer: results of a five-year study. Dis Colon Rectum, 44(2): 231–235

[88] Wolmark N, Fisher B, Rockette H, Redmond C, Wickerham D L, Fisher E R, Jones J, Glass A, Lerner H, Lawrence W, Prager D, Wexler M, Evans J, Cruz A, Dimitrov N, Jochimsen P (1988). Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol C-01. J Natl Cancer Inst, 80(1): 30–36

[89] Yeh C S, Wang J Y, Wu C H, Chong I W, Chung F Y, Wang Y H, Yu Y P, Lin S R (2006). Molecular detection of circulating cancer cells in the peripheral blood of patients with colorectal cancer by using membrane array with a multiple mRNA marker panel. Int J Oncol, 28(2): 411–420

RIGHTS & PERMISSIONS

2014 Higher Education Press and Springer-Verlag Berlin Heidelberg